SPRB · TickerCove

SPRBSpruce Biosciences, Inc.Healthcare · Biotechnologyas of 2026-09-16

Horizon

Issued 2026-09-16 at $54.16 · now $54.16 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, SPRB has typically landed between $33.51 and $83.76 — a range of −38.1% to +54.6% from the issuance price $54.16.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

1,465 overlapping 1 month windows · 2020-10-09 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($54.16) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$54.16 · 27% of range

$7.75 low$182.6 high

Trailing 52 weeks to 2026-09-16 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,408 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.9%

90% CI 51.7%–56.1%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−5.1%

typical move · IQR 29.4%

−38.1%worst (p90)+54.6%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where SPRB has typically landed a month from the 2026-09-16 close of $54.16 — the range is history, not a prediction.

now $54.16 (+0.0%)
typical $51.38 (-5.1%)
middle 50% $43.43–$59.33
90% range $33.51–$83.76

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,465 windows spanning 2020-10-09 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2024-02-23	−87.2%	−87.2%	+0.0%
2024-02-22	−86.5%	−86.5%	+2.4%
2024-03-13	−86.4%	−86.5%	+0.0%
3 best
2025-09-05	+1928.9%	−13.9%	+1928.9%
2025-09-09	+1847.9%	−13.9%	+1928.9%
2025-09-11	+1706.9%	−11.9%	+1975.0%

1,465 overlapping windows · 2020-10-09 – 2026-09-16 · not cherry-picked

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

33%

+19.1%

n=6

Feb

50%

−3.6%

n=6

Mar

17%

−20.9%

n=6

Apr

−19.4%

n=6

May

33%

−5.0%

n=6

Jun

50%

−5.5%

n=6

Jul

50%

+3.8%

n=6

Aug

33%

+2.4%

n=6

Sep

50%

−6.1%

n=6

Oct

40%

+210.5%

n=5

Nov

50%

+0.1%

n=6

Dec

33%

+21.8%

n=6

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2025-10-06	Parkman Healthcare Partners LLC	tenPercentOwner	Purchase	256 @ $17.91	$5K	+24.4% of holding	+1088.9%	+620.1%	1,307	Form 4 · filed 2 days after the trade
2025-10-06	Parkman Healthcare Partners LLC	tenPercentOwner	Purchase	256 @ $17.91	$5K	+24.4% of holding	+1088.9%	+620.1%	1,307	Form 4 · filed 9 days after the trade
2025-10-06	Parkman Healthcare Partners LLC	tenPercentOwner	Sale	232 @ $19.33	$4K	−17.8% of holding	+1088.9%	+620.1%	1,075	Form 4 · filed 2 days after the trade
2025-10-06	Parkman Healthcare Partners LLC	tenPercentOwner	Sale	232 @ $19.33	$4K	−17.8% of holding	+1088.9%	+620.1%	1,075	Form 4 · filed 9 days after the trade
2025-10-06	Parkman Healthcare Partners LLC	tenPercentOwner	Sale	25 @ $17.46	$436	−2.3% of holding	+1088.9%	+620.1%	1,050	Form 4 · filed 2 days after the trade
2025-10-06	Parkman Healthcare Partners LLC	tenPercentOwner	Sale	25 @ $17.46	$436	−2.3% of holding	+1088.9%	+620.1%	1,050	Form 4 · filed 9 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

173 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-07-27	Quartel Adrian W	officer	Award / grant	13,000	13,000	Form 4
2026-06-30	Szwarcberg Javier B.	director	Award / grant	266	19,270	Form 4
2026-05-21	Barretto-Ko Percival	director	Award / grant	1,700	1,700	Form 4
2026-05-21	SIMPSON CAMILLA V	director	Award / grant	1,700	1,700	Form 4
2026-05-21	SPIEGELMAN DANIEL K	director	Award / grant	1,700	1,700	Form 4
2026-05-21	Walbert Keli	director	Award / grant	1,700	1,700	Form 4
2026-05-21	GREY MICHAEL G	director	Award / grant	1,700	1,700	Form 4
2026-03-09	Hooks Corwin Dale	officer	Award / grant	11,000	11,000	Form 4
2025-12-31	Szwarcberg Javier B.	director	Award / grant	4,690	19,004	Form 4
2025-12-15	Szwarcberg Javier B.	director	Withheld for tax	752	13,726	Form 4
2025-12-15	Szwarcberg Javier B.	director	Withheld for tax	608	14,314	Form 4
2025-12-15	Gharib Samir M.	officer	Withheld for tax	184	8,263	Form 4
2025-12-15	Gharib Samir M.	officer	Withheld for tax	178	7,934	Form 4
2025-12-15	Szwarcberg Javier B.	director	Option exercise	1,480	14,478	Form 4
2025-12-15	Gharib Samir M.	officer	Option exercise	496	8,112	Form 4
2025-12-15	Gharib Samir M.	officer	Option exercise	513	8,447	Form 4
2025-12-15	Gharib Samir M.	officer	Option exercise	496	497	Form 4
2025-12-15	Gharib Samir M.	officer	Option exercise	513	1,027	Form 4
2025-12-15	Szwarcberg Javier B.	director	Option exercise	1,196	14,922	Form 4
2025-12-15	Szwarcberg Javier B.	director	Option exercise	1,196	2,392	Form 4
2025-12-15	Szwarcberg Javier B.	director	Option exercise	1,480	1,480	Form 4
2025-12-11	Szwarcberg Javier B.	director	Withheld for tax	2,194	12,998	Form 4
2025-12-11	Gharib Samir M.	officer	Withheld for tax	680	7,616	Form 4
2025-12-11	Walbert Keli	director	Award / grant	3,400	3,400	Form 4
2025-12-11	Ways Douglas Kirk	director	Option exercise	1,250	3,750	Form 4
2025-12-11	Ways Douglas Kirk	director	Option exercise	1,250	1,250	Form 4
2025-12-11	Szwarcberg Javier B.	director	Option exercise	4,950	14,850	Form 4
2025-12-11	Ways Douglas Kirk	director	Award / grant	5,000	5,000	Form 4
2025-12-11	Szwarcberg Javier B.	director	Award / grant	19,800	19,800	Form 4
2025-12-11	Szwarcberg Javier B.	director	Option exercise	4,950	15,192	Form 4
2025-12-11	Gharib Samir M.	officer	Option exercise	1,900	5,700	Form 4
2025-12-11	Gharib Samir M.	officer	Award / grant	7,600	7,600	Form 4
2025-12-11	Gharib Samir M.	officer	Option exercise	1,900	8,296	Form 4
2025-12-11	GREY MICHAEL G	director	Disposition	400	0	Form 4
2025-12-11	SPIEGELMAN DANIEL K	director	Disposition	88	0	Form 4
2025-12-11	SPIEGELMAN DANIEL K	director	Award / grant	400	400	Form 4
2025-12-11	SPIEGELMAN DANIEL K	director	Disposition	400	0	Form 4
2025-12-11	GREY MICHAEL G	director	Award / grant	387	387	Form 4
2025-12-11	GREY MICHAEL G	director	Disposition	387	0	Form 4
2025-12-11	GREY MICHAEL G	director	Award / grant	1,255	1,255	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

28d remaining

2026-09-173% elapsed2026-10-15

Logged immutably 2026-09-17; scored automatically on 2026-10-15 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i